Stock CGEM CULLINAN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Cullinan Therapeutics, Inc.

Equities

CGEM

US2300311063

Real-time Estimate Cboe BZX
Other stock markets
 10:06:33 2024-04-19 am EDT 		5-day change 1st Jan Change
17.98 USD -0.47% Intraday chart for Cullinan Therapeutics, Inc. +9.42% +79.00%
Apr. 16 Transcript : Cullinan Oncology, Inc. - Special Call
Apr. 16 Cullinan Oncology, Inc. Announces Important Updates About Its Plan to Expand into Autoimmune Diseases, the Scientific Rationale for Developing CLN-978 in Autoimmune Diseases CI

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
CULLINAN ONCOLOGY : Morgan Stanley Adjusts Cullinan Oncology's Price Target to $43 From $40, Maintains Overweight Rating
MT
CULLINAN ONCOLOGY : HC Wainwright Adjusts Cullinan Management PT to $55 From $48, Maintains Buy Rating
MT
CULLINAN ONCOLOGY : SVB Leerink Adjusts Price Target on Cullinan Management to $54 From $48, Maintains Outperform Rating
MT
CULLINAN ONCOLOGY : Morgan Stanley Upgrades Cullinan Management to Overweight from Equalweight, Sets $40 Price Target
MT
CULLINAN ONCOLOGY : Morgan Stanley Adjusts Price Target on Cullinan Management to $40 From $38, Maintains Equal-Weight Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CGEM Stock
  4. News Cullinan Therapeutics, Inc.
  5. Analyst Reco.